πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 2,828 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10392368

Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors

Theravance Biopharma R&D IP, LLC Β· Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10391097

Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors

VTV THERAPEUTICS LLC Β· Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10391095

DNA-PK inhibitors

Vertex Pharmaceuticals Incorporated Β· Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10385080

STAT6 inhibitors

The Board of Regents of the University of Texas System Β· Granted Tue Aug 20 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 15 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10385031

Substituted piperazines as selective HDAC1,2 inhibitors

Regenacy Pharmaceuticals, Inc. Β· Granted Tue Aug 20 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 15 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10377772

Macrocyclic LRRK2 kinase inhibitors

Oncodesign SA Β· Granted Tue Aug 13 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10376515

Analogs of adenosine monophosphate (AMP) as inhibitors of ubiquitin-like modifier-activati

Northwestern University Β· Granted Tue Aug 13 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10376510

2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of ca

Agios Pharmaceuticals, Inc. Β· Granted Tue Aug 13 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10370371

Substituted pyrimidine Bmi-1 inhibitors

PTC THERAPEUTICS, INC. Β· Granted Tue Aug 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10370367

IRAK inhibitors and method for making and using

Rigel Pharmaceuticals, Inc. Β· Granted Tue Aug 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10370360

Small-molecule inhibitors targeting discoidin domain receptor 1 and uses thereof

The Board of Regents of the University of Texas System Β· Granted Tue Aug 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10370333

Sulfonamide compounds and uses as TNAP inhibitors

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE Β· Granted Tue Aug 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10364258

Heteroaryl inhibitors of PDE4

Tetra Discovery Partners Β· Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10364238

N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors

KalVista Pharmaceuticals Limited Β· Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10363261

Enolase inhibitors and methods of treatment therewith

The Board of Regents of the University of Texas System Β· Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10358421

Piperidine derivatives as HDAC1/2 inhibitors

Regenacy Pharmaceuticals, Inc. Β· Granted Tue Jul 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10351532

Small molecule inhibitors of lactate dehydrogenase and methods of use thereof

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jul 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10344033

2-aminoquinazoline derivatives as P70S6 kinase inhibitors

SENTINEL ONCOLOGY LIMITED Β· Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10344025

GLS1 inhibitors for treating disease

The Board of Regents of the University of Texas System Β· Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10342786

P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Fulcrum Therapeutics, Inc. Β· Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10342764

Protease inhibitor-containing compositions, compositions comprising same, and methods for

Oramed Ltd. Β· Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10337005

Oligonucleotide-based inhibitors comprising locked nucleic acid motif

MIRAGEN THERAPEUTICS, INC. Β· Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10336773

Neprilysin inhibitors

Theravance Biopharma R&D IP, LLC Β· Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10335404

Methods of treating cancer patients with farnesyltransferase inhibitors

Kura Oncology, Inc. Β· Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted